{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:01:31Z","timestamp":1792422091651,"version":"4.5.0"},"reference-count":76,"publisher":"Japan Endocrine Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1507\/endocrj.ej25-0559","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T22:08:36Z","timestamp":1775081316000},"page":"799-810","source":"Crossref","is-referenced-by-count":2,"title":["Double faces of pheochromocytoma and paraganglioma\u2014a review of integrated pathologic diagnosis"],"prefix":"10.1507","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8160-3687","authenticated-orcid":false,"given":"Noriko","family":"Kimura","sequence":"first","affiliation":[{"name":"Department of Diagnostic Pathology, National Hospital Organization Hakodate Medical Center, Hakodate 041-8512, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Solcia E, Kloppel G, Sobin LH (2000) Tumours of adrenal and extra-adrenal paraganglia. In: Solcia E, Kloppel G, Sobin LH (eds). WHO International Histological Classification of Tumours: Histological typing of endocrine tumours (2nd). Springer, Berlin, Germany: 38\u201344.","DOI":"10.1007\/978-3-642-59655-1"},{"key":"2","unstructured":"2 Tischler AS, de Krijer RR, Gill A, Kawashima A, Kimura N, et al. (2017) Pheochromocytoma. In: Lloyd RV, Osamura RY, Kloppel G, Rosai J (eds). WHO Classification of Tumours of Endocrine Organs (4th). IARC, Lyon, France: 181\u2013189."},{"key":"3","unstructured":"3 Kimura N, Capella C, DeLellis RA, Epstein JI, Gill A, et al. (2017) Extra-adrenal paraganliomas. In: Lloyd RV, Osamura RY, Kloppel G, Rosai J (eds). WHO Classification of Tumours of Endocrine Organs (4th). IARC, Lyon, France: 190\u2013195."},{"key":"4","unstructured":"4 De Krijer RR, Erickson LA, Gill AJ (2022) Adrenal medulla and extra-adrenal paraganglia tumours. In: WHO Classification of Tumours Editorial Board (eds). WHO Classification of Tumours: Endocrine and Neuroendocrine Tumours (5th). IARC, Lyon, France: 277\u2013294."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Kimura N, Sasano N, Miura Y, Kobayashi K (1984) Adrenal and extra-adrenal pheochromocytomas: an ultrastructural and formaldehyde-induced fluorescence study with catecholamine content. Tohoku J Exp Med 142: 1\u201314.","DOI":"10.1620\/tjem.142.1"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Lloyd RV (ed) (1990) Endocrine Pathology. Springer-Verlag, New York, USA: 1\u20138.","DOI":"10.1007\/978-1-4612-3346-6_1"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Kimura N, Sasano N, Yamada R, Satoh J (1988) Immunohistochemical study of chromogranin in 100 cases of pheochromocytoma, carotid body tumour, medullary thyroid carcinoma and carcinoid tumour. Virchows Arch A Pathol Anat Histopathol 413: 33\u201338.","DOI":"10.1007\/BF00844279"},{"key":"8","unstructured":"8 Lloyd RV, Cano M, Rosa P, Hille A, Huttner WB (1988) Distribution of chromogranin A and secretogranin I (chromogranin B) in neuroendocrine cells and tumors. Am J Pathol 130: 296\u2013304."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Kimura N, Pilichowska M, Okamoto H, Kimura I, Aunis D (2000) Immunohistochemical expression of chromogranins A and B, prohormone convertases 2 and 3, and amidating enzyme in carcinoid tumors and pancreatic endocrine tumors. Mod Pathol 13: 140\u2013146.","DOI":"10.1038\/modpathol.3880026"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Linnoila RI, Keiser HR, Steinberg SM, Lack EE (1990) Histopathology of benign <i>versus<\/i> malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum Pathol 21: 1168\u20131180.","DOI":"10.1016\/0046-8177(90)90155-X"},{"key":"11","unstructured":"11 Kimura N, Sasano N (1990) A comparative study between malignant and benign pheochromocytoma using morphometry, cytophotometry, and immunohistochemistry. In: Lechago J, Kameya T (eds). Endocrine Pathology Update vol 1. Field &amp; Wood, New York, USA: 99\u2013118."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Kimura N, Watanabe M, Ookuma T, Miura W, Noshiro T, et al. (1994) Dna ploidy of pheochromocytoma on cytology specimen by image analysis. Endocr Pathol 5: 178\u2013182.","DOI":"10.1007\/BF02921474"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Kimura N, Watanabe T, Noshiro T, Shizawa S, Miura Y (2005) Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors. Endocr Pathol 16: 23\u201332.","DOI":"10.1385\/EP:16:1:023"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Eisenhofer G, Bornstein SR, Brouwers FM, Cheung NK, Dahia PL, et al. (2004) Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 11: 423\u2013436.","DOI":"10.1677\/erc.1.00829"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Kimura N, Miura W, Noshiro T, Miura Y, Ookuma T, et al. (1994) Ki-67 is an indicator of progression of neuroendocrine tumors. Endocr Pathol 5: 223\u2013228.","DOI":"10.1007\/BF02921490"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 van der Harst E, Bruining HA, Jaap Bonjer H, van der Ham F, Dinjens WN, et al. (2000) Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases? J Pathol 191: 175\u2013180.","DOI":"10.1002\/(SICI)1096-9896(200006)191:2<175::AID-PATH615>3.0.CO;2-Z"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Pacak K, Eisenhofer G (2006) Pheochromocytoma: First International Symposium. Ann NY Acad Sci 1073.","DOI":"10.1002\/9780470692196"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Tischler AS, Kimura N, McNicol AM (2006) Pathology of pheochromocytoma and extra-adrenal paraganglioma. Ann N Y Acad Sci 1073: 557\u2013570.","DOI":"10.1196\/annals.1353.059"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Thompson LD (2002) Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 26: 551\u2013566.","DOI":"10.1097\/00000478-200205000-00002"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Lack EE (2007) Pheochromocytoma, extraadrenal paraganglia, paragangliomas, and other features of sympathoadrenal paragangliomas. In: Tumors of the Adrenal Glands and Extaadrenal Paraganglia. AFIP Atlas of Tumor Pathology Series 4. American Registry Pathology and AFIP, Washington DC, USA: 241\u2013282, 283\u2013322, 292\u2013293.","DOI":"10.55418\/9781881041016-11"},{"key":"21","unstructured":"21 Naruse M, Tsuiki M, Nanba K, Nakao K, Tagami T, et al. (2012) Etiology and clinical guidelines for the diagnosis and treatment of pheochromocytoma in Japan. Nihon Geka Gakkai Zasshi 113: 378\u2013383 (In Japanese)."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Tanabe A, Katabami T, Hashimoto S, Izawa S, Ichijo T, et al. (2026) Japan Endocrine Society Clinical Practice Guideline for the Diagnosis and Management of Pheochromocytoma and Paraganglioma 2025. Endocr J 73: 115\u2013157.","DOI":"10.1507\/endocrj.EJ25-0165"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Kimura N, Takayanagi R, Takizawa N, Itagaki E, Katabami T, et al. (2014) Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma. Endocr Relat Cancer 21: 405\u2013414.","DOI":"10.1530\/ERC-13-0494"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Yonamine M, Wasano K, Aita Y, Sugasawa T, Takahashi K, et al. (2021) Prevalence of germline variants in a large cohort of Japanese patients with pheochromocytoma and\/or paraganglioma. Cancers (Basel) 13: 4014.","DOI":"10.3390\/cancers13164014"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Eisenhofer G, Tischler AS (2014) Neuroendocrine cancer. Closing the GAPP on predicting metastases. Nat Rev Endocrinol 10: 315\u2013316.","DOI":"10.1038\/nrendo.2014.41"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Kimura N, Takekoshi K, Horii A, Morimoto R, Imai T, et al. (2014) Clinicopathological study of SDHB mutation-related pheochromocytoma and sympathetic paraganglioma. Endocr Relat Cancer 21: L13\u2013L16.","DOI":"10.1530\/ERC-13-0530"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Papathomas TG, Oudijk L, Persu A, Gill AJ, van Nederveen F, et al. (2015) SDHB\/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). Mod Pathol 28: 807\u2013821.","DOI":"10.1038\/modpathol.2015.41"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Kimura N, Muroya K, Yonamine M, Takekoshi K, Sato T, et al. (2025) Clinicopathological and genomic analysis of pediatric pheochromocytoma and sympathetic paraganglioma. Endocr J 72: 399\u2013412.","DOI":"10.1507\/endocrj.EJ24-0584"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Matsuda Y, Kimura N, Yoshimoto T, Sekiguchi Y, Tomoishi J, et al. (2017) Dopamine-secreting paraganglioma in the retroperitoneum. Endocr Pathol 28: 36\u201340.","DOI":"10.1007\/s12022-016-9457-0"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Miyamoto S, Yoshida Y, Ozeki Y, Okamoto M, Gotoh K, et al. (2021) Dopamine-secreting pheochromocytoma and paraganglioma. J Endocr Soc 5: bvab163.","DOI":"10.1210\/jendso\/bvab163"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Bellezza G, Giansanti M, Cavaliere A, Sidoni A (2004) Pigmented \u201cblack\u201d pheochromocytoma of the adrenal gland: a case report and review of the literature. Arch Pathol Lab Med 128: e125\u2013e128.","DOI":"10.5858\/2004-128-e125-PBPOTA"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Pierre C, Agopiantz M, Brunaud L, Battaglia-Hsu SF, Max A, et al. (2019) COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas\/paragangliomas. Virchows Arch 474: 721\u2013734.","DOI":"10.1007\/s00428-019-02553-5"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Wachtel H, Hutchens T, Baraban E, Schwartz LE, Montone K, et al. (2020) Predicting metastatic potential in pheochromocytoma and paraganglioma: a comparison of PASS and GAPP scoring systems. J Clin Endocrinol Metab 105: e4661\u2013e4670.","DOI":"10.1210\/clinem\/dgaa608"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Koh JM, Ahn SH, Kim H, Kim BJ, Sung TY, et al. (2017) Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma. PLoS One 12: e0187398.","DOI":"10.1371\/journal.pone.0187398"},{"key":"35","unstructured":"35 Wang Y, Li M, Deng H, Pang Y, Liu L, et al. (2020) The systems of metastatic potential prediction in pheochromocytoma and paraganglioma. Am J Cancer Res 10: 769\u2013780."},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Mete O, Asa SL, Gill AJ, Kimura N, de Krijger RR, et al. (2022) Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas. Endocr Pathol 33: 90\u2013114.","DOI":"10.1007\/s12022-022-09704-6"},{"key":"37","unstructured":"37 Klimstra DS, Mete O, Osamura RY, Washington MK (2022) Pancreatic neuroendocrine neoplasms. In: WHO Editorial Board (ed). WHO Tumour Classification: Endocrine and Neuroendocrine Tumours (5th). IARC, Lyon, France: 295\u2013299."},{"key":"38","unstructured":"38 Asa S, Klimstra DS, Mete O, Osamura RY, Rindi G (2022) Neuroendocrine neoplasms in non-endocrine organs. In: WHO Editorial Board (ed). WHO Classification of Tumours: Endocrine and Neuroendocrine Tumours (5th). IARC, Lyon, France: 332\u2013345."},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Rosenbaum JN, Guo Z, Baus RM, Werner H, Rehrauer WM, et al. (2015) INSM1: a novel immunohistochemical and molecular marker for neuroendocrine and neuroepithelial neoplasms. Am J Clin Pathol 144: 579\u2013591.","DOI":"10.1309\/AJCPGZWXXBSNL4VD"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Nonaka D, Wang BY, Edmondson D, Beckett E, Sun CC (2013) A study of gata3 and phox2b expression in tumors of the autonomic nervous system. Am J Surg Pathol 37: 1236\u20131241.","DOI":"10.1097\/PAS.0b013e318289c765"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Miyauchi M, Akashi T, Furukawa A, Uchida K, Tamura T, et al. (2022) PHOX2B is a sensitive and specific marker for the histopathological diagnosis of pheochromocytoma and paraganglioma. Endocr Pathol 33: 506\u2013518.","DOI":"10.1007\/s12022-022-09730-4"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Kimura N, Shiga K, Kaneko K, Sugisawa C, Katabami T, et al. (2020) The diagnostic dilemma of GATA3 immunohistochemistry in pheochromocytoma and paraganglioma. Endocr Pathol 31: 95\u2013100.","DOI":"10.1007\/s12022-020-09618-1"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Kimura N, Miura Y, Nagatsu I, Nagura H (1992) Catecholamine synthesizing enzymes in 70 cases of functioning and non-functioning phaeochromocytoma and extra-adrenal paraganglioma. Virchows Arch A Pathol Anat Histopathol 421: 25\u201332.","DOI":"10.1007\/BF01607135"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Kimura N (2021) Dopamine \u03b2-hydroxylase: an essential and optimal immunohistochemical marker for pheochromocytoma and sympathetic paraganglioma. Endocr Pathol 32: 258\u2013261.","DOI":"10.1007\/s12022-020-09655-w"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Timmers HJ, Pacak K, Huynh TT, Abu-Asab M, Tsokos M, et al. (2008) Biochemically silent abdominal paragangliomas in patients with mutations in the succinate dehydrogenase subunit B gene. J Clin Endocrinol Metab 93: 4826\u20134832.","DOI":"10.1210\/jc.2008-1093"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Tanaka T, Joraku A, Ishibashi S, Endo K, Emura M, et al. (2023) Abdominal nonfunctional paraganglioma in which succinate dehydrogenase subunit B (SDHB) immunostaining was performed: a case report. J Med Case Rep 17: 106.","DOI":"10.1186\/s13256-023-03822-3"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47 Kimura N, Shiga K, Kaneko KI, Oki Y, Sugisawa C, et al. (2021) Immunohistochemical expression of choline acetyltransferase and catecholamine-synthesizing enzymes in head-and-neck and thoracoabdominal paragangliomas and pheochromocytomas. Endocr Pathol 32: 442\u2013451.","DOI":"10.1007\/s12022-021-09694-x"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 Thompson LDR, Gill AJ, Asa SL, Clifton-Bligh RJ, de Krijger RR, et al. (2021) Data set for the reporting of pheochromocytoma and paraganglioma: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. Hum Pathol 110: 83\u201397.","DOI":"10.1016\/j.humpath.2020.04.012"},{"key":"49","unstructured":"49 Tischler AS, Assie G, Erickson LA, Lam AK, Mete O, et al. (2022) Phaochromocytoma. In: WHO Editorial Board (ed). WHO Tumour Classification: Endocrine and Neuroendocrine Tumours (5th). IARC, Lyon, France: 277\u2013287."},{"key":"50","doi-asserted-by":"crossref","unstructured":"50 Jochmanova I, Pacak K (2018) Genomic landscape of pheochromocytoma and paraganglioma. Trends Cancer 4: 6\u20139.","DOI":"10.1016\/j.trecan.2017.11.001"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51 Romanet P, Guerin C, Pedini P, Essamet W, Castinetti F, et al. (2017) Pathological and genetic characterization of bilateral adrenomedullary hyperplasia in a patient with germline MAX mutation. Endocr Pathol 28: 302\u2013307.","DOI":"10.1007\/s12022-016-9460-5"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52 van Nederveen FH, Gaal J, Favier J, Korpershoek E, Oldenburg RA, et al. (2009) An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis. Lancet Oncol 10: 764\u2013771.","DOI":"10.1016\/S1470-2045(09)70164-0"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53 Eisenhofer G, Pacak K, Huynh TT, Qin N, Bratslavsky G, et al. (2011) Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocr Relat Cancer 18: 97\u2013111.","DOI":"10.1677\/ERC-10-0211"},{"key":"54","unstructured":"54 Gill AJ, Agaimy A, Asa SL, de Krejger RR, Erickson LA, et al. (2025) SDH-deficient tumour syndromes. In: WHO Editorial Board (ed). WHO Classification of Tumours: Endocrine and Neuroendocrine Tumours (5th). IARC, Lyon, France: 457\u2013462."},{"key":"55","doi-asserted-by":"crossref","unstructured":"55 Kawanabe S, Katabami T, Oshima R, Yanagisawa N, Sone M, et al. (2022) A rare case of multiple paragangliomas in the head and neck, retroperitoneum and duodenum: a case report and review of the literature. Front Endocrinol (Lausanne) 13: 1054468.","DOI":"10.3389\/fendo.2022.1054468"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56 Asa SL, Ezzat S, Mete O (2018) The diagnosis and clinical significance of paragangliomas in unusual locations. J Clin Med 7: 280.","DOI":"10.3390\/jcm7090280"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57 Kimura N, Ishikawa M, Shigematsu K (2022) Colorectal paragangliomas with immunohistochemical deficiency of succinate dehydrogenase subunit B. Endocr J 69: 523\u2013528.","DOI":"10.1507\/endocrj.EJ21-0630"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58 Pinato DJ, Ramachandran R, Toussi ST, Vergine M, Ngo N, et al. (2012) Immunohistochemical markers of the hypoxic response can identify malignancy in phaeochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutations. Br J Cancer 108: 429\u2013437.","DOI":"10.1038\/bjc.2012.538"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59 Favier J, Meatchi T, Robidel E, Badoual C, Sibony M, et al. (2020) Carbonic anhydrase 9 immunohistochemistry as a tool to predict or validate germline and somatic VHL mutations in pheochromocytoma and paraganglioma-a retrospective and prospective study. Mod Pathol 33: 57\u201364.","DOI":"10.1038\/s41379-019-0343-4"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60 Burnichon N, Casc\u00f3n A, Schiavi F, Morales NP, Comino-M\u00e9ndez I, et al. (2012) MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res 18: 2828\u20132837.","DOI":"10.1158\/1078-0432.CCR-12-0160"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61 Kimura N (2015) A pathologist\u2019s view: molecular profiles for diagnosing pheochromocytomas and paragangliomas. Int J Endocrine Oncol 2: 193\u2013200.","DOI":"10.2217\/ije.15.16"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62 Seabrook AJ, Harris JE, Velosa SB, Kim E, McInerney-Leo AM, et al. (2021) Multiple endocrine tumors associated with germline MAX mutations: multiple endocrine neoplasia type 5? J Clin Endocrinol Metab 106: 1163\u20131182.","DOI":"10.1210\/clinem\/dgaa957"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63 Curr\u00e1s-Freixes M, Inglada-P\u00e9rez L, Mancikova V, Montero-Conde C, Let\u00f3n R, et al. (2015) Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients. J Med Genet 52: 647\u2013656.","DOI":"10.1136\/jmedgenet-2015-103218"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64 Favier J, Amar L, Gimenez-Roqueplo AP (2015) Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nat Rev Endocrinol 11: 101\u2013111.","DOI":"10.1038\/nrendo.2014.188"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65 Dhanasekar K, Visakan V, Tahir F, Balasubramanian SP (2022) Composite phaeochromocytomas-a systematic review of published literature. Langenbecks Arch Surg 407: 517\u2013527.","DOI":"10.1007\/s00423-021-02129-5"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66 Kimura N, Miura Y, Miura K, Takahashi N, Osamura RY, et al. (1991) Adrenal and retroperitoneal mixed neuroendocrine-neural tumors. Endocr Pathol 2: 139\u2013147.","DOI":"10.1007\/BF02915454"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67 Ratner N, Miller SJ (2015) A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat Rev Cancer 15: 290\u2013301.","DOI":"10.1038\/nrc3911"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68 Kimura N, Fukase M, Wakita A, Kimura I (2002) Loss of the neurofibromin-NF1 gene product and composite pheochromocytoma. Ann N Y Acad Sci 971: 536\u2013538.","DOI":"10.1111\/j.1749-6632.2002.tb04521.x"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69 Kimura N, Watanabe T, Fukase M, Wakita A, Noshiro T, et al. (2002) Neurofibromin and NF1 gene analysis in composite pheochromocytoma and tumors associated with von Recklinghausen\u2019s disease. Mod Pathol 15: 183\u2013188.","DOI":"10.1038\/modpathol.3880513"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70 Korpershoek E, Petri BJ, Post E, van Eijck CH, Oldenburg RA, et al. (2014) Adrenal medullary hyperplasia is a precursor lesion for pheochromocytoma in MEN2 syndrome. Neoplasia 16: 868\u2013873.","DOI":"10.1016\/j.neo.2014.09.002"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71 Elliott PF, Berhane T, Ragnarsson O, Falhammar H (2021) Ectopic ACTH- and\/or CRH-producing pheochromocytomas. J Clin Endocrinol Metab 106: 598\u2013608.","DOI":"10.1210\/clinem\/dgaa488"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72 Kishlyansky D, Leung AA, Pasieka JL, Mahajan A, Kline GA (2024) Cushing syndrome from an ACTH-producing pheochromocytoma or paraganglioma: structured review of 94 cases. Endocr Relat Cancer 31: e240029.","DOI":"10.1530\/ERC-24-0029"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73 Saishouji F, Maeda S, Hamada H, Kimura N, Tamanoi A, et al. (2022) Ectopic ACTH-producing neuroendocrine tumor occurring with large recurrent metastatic pheochromocytoma: a case report. BMC Endocr Disord 22: 184.","DOI":"10.1186\/s12902-022-01090-8"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74 Mathison DA, Waterhouse CA (1969) Cushing\u2019s syndrome with hypertensive crisis and mixed adrenal cortical adenoma-pheochromocytoma (corticomedullary adenoma). Am J Med 47: 635\u2013641.","DOI":"10.1016\/0002-9343(69)90193-4"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75 Kimura N, Motoyama T, Saito J, Nishikawa T (2022) Mixed corticomedullary tumor of the adrenal gland. Front Endocrinol (Lausanne) 13: 1026918.","DOI":"10.3389\/fendo.2022.1026918"},{"key":"76","unstructured":"76 Gorbman A DW, Vigna SR, Clark NB, Ralph CL (1983) The adrenal medulla. In: Comparative Endocrinology. John Wiley &amp; Sons, New York, USA: 373\u2013377."}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/73\/7\/73_EJ25-0559\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T03:43:32Z","timestamp":1783136612000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/73\/7\/73_EJ25-0559\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":76,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej25-0559","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"EJ25-0559"}}